Clinical Trial

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-02-25; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2021-07-24
Trial Details
NCT Number NCT04775745
Lead Sponsor Newave Pharmaceutical Inc
Conditions CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
Enrollment 60 participants
Start Date 2021-07-19
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13